Loredana Smarandache, MD

The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.

Research reveals how COVID-19 disrupted anti-VEGF treatment schedules, yet flexible regimens maintain visual outcomes for neovascular AMD patients.